Apimeds Brings ai² Futures Lab to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Futures Lab program through a new collaboration with the University of Idaho College of Business and Economics, beginning in the Spring 2026 semester. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds’ commitment to fostering innovation, leadership, and discovery across the healthcare ecosystem.

The ai² Futures Lab functions as both a discovery engine for potential therapeutic assets and a training ground for the next generation of biotech and business leaders. Through this collaboration, University of Idaho students will work alongside Apimeds mentors to evaluate early-stage pharmaceutical assets, perform market and IP analysis, and identify novel strategies to improve patient care and expand therapeutic opportunities.

“We’re thrilled to bring the ai² Futures Lab to the University of Idaho,” said Brian Peters, SVP of the ai² Division at Apimeds Pharmaceuticals. “This program is designed to spark real innovation by connecting bright, ambitious students with real-world biotech challenges. The entrepreneurial spirit and collaborative culture at Idaho align perfectly with our mission to blend business acumen and scientific insight into actionable solutions for patients.”

Mark Groza, Director of Distance Education and Professor of Marketing at the University of Idaho College of Business and Economics, added: “By strengthening our partnerships with industry and providing experiential learning opportunities for our MBA students, this collaboration directly supports the University of Idaho’s land-grant mission and core pillars of our strategic plan. It gives our students a front-row seat to where business strategy, science, and innovation intersect. Working with Apimeds allows them to apply classroom concepts in a high-impact, hands-on environment and will help prepare them to lead in emerging sectors such as biotechnology and healthcare.”

Erik Emerson, CEO of Apimeds Pharmaceuticals, emphasized the growing reach of the ai² Futures Lab initiative: “The expansion of ai² Futures Lab into Idaho marks another important milestone in building an ecosystem where education and innovation meet. Each new partnership strengthens our ability to cultivate fresh perspectives, inspire future leaders, and accelerate discovery in meaningful ways.”